A phase 1, single center, open-label, randomized, single-dose, two-way crossover study analyzing pharmacokinetic of Test Pediatric Formulation of Ezogabine (XEN496) in Healthy Adult Volunteers
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Retigabine (Primary)
- Indications Early infantile epileptic encephalopathy 2
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Xenon Pharmaceuticals
Most Recent Events
- 05 Apr 2022 Results assessing the effect of food on the pharmacokinetics of XEN496 and its N-acetyl metabolite in healthy volunteers, published in the Neurology and Therapy
- 08 Dec 2020 Results evaluating pk of Retigabine presented at the 74th Annual Meeting of the American Epilepsy Society
- 01 May 2020 Trial design, presented at the 72nd Annual Meeting of the American Academy of Neurology